What You Should Know:
– Neoplas Med GmbH, a Greifswald-based medical technology company, has secured an $18M investment from Niterra Ventures Company to further develop and expand its innovative cold plasma wound care technology.
– The latest investment brings Niterra’s total investment in Neoplas Med to $25M, following previous funding rounds in 2022 and 2023.
Transforming Wound Care with Cold Plasma
Neoplas Med is a pioneer in the field of cold plasma technology for medical applications. The company is the only manufacturer of cold plasma products in Europe with European Medical Device Regulation (MDR) certification. Its patented argon jet cold plasma therapy is widely used in leading clinics across Europe and the Middle East. Neoplas Med has developed kINPen® MED, a pioneering “plasma pen” that utilizes argon cold plasma to accelerate wound healing. This innovative technology offers significant advantages over conventional wound care methods:
- Faster Healing: Clinical studies have shown that kINPen® MED can reduce wound healing time by up to 50% compared to traditional treatments.
- Painless and Safe: The argon cold plasma jet is virtually painless and has no known side effects or risk of developing resistance.
- Effective for Various Wounds: The technology can be used to treat both infected and chronic wounds.
This new funding will enable Neoplas Med to:
- Further develop its technology platform: Enhance the capabilities and applications of its cold plasma technology.
- Scale international operations: Expand its reach into new markets, particularly the US, Europe, and the Middle East.
Increase production capacity: Meet the growing demand for its innovative wound care solutions.
